Paper Details

  1. Home
  2. Paper Details

Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache.

Author: AndrewsJ Scott, BardosJennifer, GaulCharly, KudrowDavid, KuruppuDulanji, MartinezJames, OakesTina, RettigantiMallikarjuna, RiesenbergRobert, WenzelRichard

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study evaluated the median time-to-first occurrence of attack frequency reduction and impact on acute treatment management in patients with episodic cluster headache (CH). The study found that galcanezumab achieved faster response rates and lower frequency of acute medication use than placebo. Galcanezumab also had a greater proportion of patients achieving a clinically meaningful attack reduction.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Cluster headache (CH) is a highly disabling primary headache disorder. To date, characterization of outcomes in the preventive treatment of episodic CH, including precise definitions of clinically meaningful attack frequency reduction and impact on acute treatment management, is lacking....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756634/

データ提供：米国国立医学図書館（NLM）

Galcanezumab: A New Hope for Episodic Cluster Headache

Cluster headache is a debilitating neurological disorder characterized by intense, recurring headaches. This study investigates the efficacy of galcanezumab, a monoclonal antibody, in the preventive treatment of episodic cluster headache. The authors analyze data from a Phase 3 randomized controlled trial, comparing the outcomes of galcanezumab treatment with placebo. They focus on the time to achieve a clinically significant reduction in headache frequency and the impact on acute medication use.

Galcanezumab: A Promising Preventive Treatment

The study's results provide encouraging evidence for the potential of galcanezumab as a preventive treatment for episodic cluster headache. The authors observed a significantly faster time to achieve a clinically significant reduction in headache frequency in patients treated with galcanezumab compared to placebo. Additionally, galcanezumab was associated with a significant reduction in acute medication use. These findings suggest that galcanezumab may offer a valuable therapeutic option for managing episodic cluster headache.

Easing the Pain of Cluster Headaches

The study's findings offer hope for individuals struggling with episodic cluster headache. Galcanezumab's potential to reduce headache frequency and decrease the need for acute medications provides a promising avenue for improving patient quality of life. The study's results highlight the importance of ongoing research into innovative treatments for cluster headache, seeking to minimize the debilitating effects of this condition.

Dr. Camel's Conclusion

Just as a camel can navigate a treacherous desert with the aid of a skilled guide, patients with episodic cluster headache may find relief through the guidance of galcanezumab. This research provides encouraging data on the efficacy of this treatment, offering hope for a future where cluster headache can be more effectively managed.

Date :
  1. Date Completed 2021-11-11
  2. Date Revised 2021-11-11
Further Info :

Pubmed ID

33179263

DOI: Digital Object Identifier

PMC7756634

Related Literature

Article Analysis
・Effective treatment of headache
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.